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Abstract
Background: Septic patients treated in the intensive care unit (ICU) often develop multiple organ failure including
persistent skeletal muscle dysfunction which results in the patient’s protracted recovery process. We have demonstrated
that muscle mitochondrial enzyme activities are impaired in septic ICU patients impairing cellular energy balance, which will
interfere with muscle function and metabolism. Here we use detailed phenotyping and genomics to elucidate mechanisms
leading to these impairments and the molecular consequences.
Methodology/Principal Findings: Utilising biopsy material from seventeen patients and ten age-matched controls we
demonstrate that neither mitochondrial in vivo protein synthesis nor expression of mitochondrial genes are compromised.
Indeed, there was partial activation of the mitochondrial biogenesis pathway involving NRF2a/GABP and its target genes
TFAM, TFB1M and TFB2M yet clearly this failed to maintain mitochondrial function. We therefore utilised transcript profiling
and pathway analysis of ICU patient skeletal muscle to generate insight into the molecular defects driving loss of muscle
function and metabolic homeostasis. Gene ontology analysis of Affymetrix analysis demonstrated substantial loss of muscle
specific genes, a global oxidative stress response related to most probably cytokine signalling, altered insulin related
signalling and a substantial overlap between patients and muscle wasting/inflammatory animal models. MicroRNA 21
processing appeared defective suggesting that post-transcriptional protein synthesis regulation is altered by disruption of
tissue microRNA expression. Finally, we were able to demonstrate that the phenotype of skeletal muscle in ICU patients is
not merely one of inactivity, it appears to be an actively remodelling tissue, influenced by several mediators, all of which
may be open to manipulation with the aim to improve clinical outcome.
Conclusions/Significance: This first combined protein and transcriptome based analysis of human skeletal muscle obtained
from septic patients demonstrated that losses of mitochondria and muscle mass are accompanied by sustained protein
synthesis (anabolic process) while dysregulation of transcription programmes appears to fail to compensate for increased
damage and proteolysis. Our analysis identified both validated and novel clinically tractable targets to manipulate these
failing processes and pursuit of these could lead to new potential treatments.
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Introduction
Yearly about 750,000 people develop severe sepsis in the USA
and probably the same amount in Europe. Total mortality for
these patients is about 30–35%, however for those patients with
persistent sepsis mortality is .50%. Most patients with persistent
sepsis develop multiple organ failure, a syndrome in which several
organ systems are malfunctioning. In order for these patients to
survive their vital organs need to be supported in the hospitals
intensive care unit (ICU). Septic patients treated in the intensive
care unit develop skeletal muscle dysfunction which is part of the
multiple organ failure syndrome, and this persists after ICU
discharge [1,2,3,4,5]. The nature of this muscle dysfunction
includes weakness due to a severe loss of muscle mass and muscle
fatigue which is most apparent during weaning of the mechanical
ventilation and results in impaired physical capacity during the
patient’s protracted recovery process [6]. In addition to the long
term failure of skeletal muscle function, rapid degeneration in the
ICU also impacts on patient acute energy metabolism and this
directs the need for concurrent interventions, such as insulin and
glucocorticoid therapy, which are principally aimed at improving
patient survival [7]. In a previous study [8] we demonstrated that
PLoS ONE | www.plosone.org 1 November 2008 | Volume 3 | Issue 11 | e3686mitochondrial content was 30–40% lower and cellular adenine
nucleotide homeostasis disrupted (lower ATP and creatine
phosphate concentrations) in skeletal muscle of ICU patients
suffering from sepsis induced multiple organ failure (MOF).
Mitochondria are the major mechanism for ATP generation in
humans and the observed lower mitochondrial content and
cellular energy status will accelerate muscle fatigue and possibly
cell death in these septic patients [9,10,11]. Indeed, mitochondrial
derangements and the subsequent disruption in energy metabo-
lism are associated with multiple organ failure and an increased
mortality in critically ill patients [12,13,14]. In addition, several
animal models of sepsis and critical illness have shown mitochon-
drial derangements in skeletal muscle and other tissues
[11,15,16,17,18] confirming the generality of these observations.
Skeletal muscle phenotype and mitochondrial content depend
on the coordinated expression of nuclear and mitochondrial
encoded genes, as well as the synthesis and degradation of proteins
to maintain normal muscle function. Mitochondrial protein
synthesis and degradation have to be in equilibrium in order for
the cell to maintain a constant number of well functioning
mitochondria. In this study we hypothesize that the lower
mitochondrial content, we found in skeletal muscle of septic
patients, is caused by a lower mitochondrial protein synthesis and
this would be regulated by lower mitochondrial gene expression.
Thus, we examined in vivo mitochondrial protein synthesis in
skeletal muscle of patients treated in the ICU for sepsis induced
MOF and compared this to age matched control subjects.
Targeted analysis of gene expression of mitochondrial oxidative
phosphorylation (OXPHOS) enzymes (both nuclear and mito-
chondrial encoded), mitochondrial proteases and master tran-
scriptional regulators of mitochondrial biogenesis presented us
with a complex picture, where selective transcriptional activation
of mitochondrial biogenesis was clearly evident. Finding clear
evidence for disrupted coordination of mitochondrial gene
expression led us to carryout a global analysis of skeletal muscle
phenotype using microarray technology to determine the extent of
altered muscle phenotype. Informatic analysis yielded profound
evidence for degeneration and loss of muscle specific genes.
Materials and Methods
Subjects
Seventeen patients admitted to the general Intensive Care Unit
(ICU) at Karolinska University Hospital Huddinge were included
in the study. The same ICU patients were also included in another
study [19]. Patients were septic according to the Bone criteria [20].
Patients younger than 18 years of age, patients with severe liver
failure, undergoing dialysis, and patients with impaired coagula-
tion were excluded from the study. As a control group 10 patients
undergoing elective surgery at Ersta Hospital (Stockholm) were
included. All patients or close relatives gave informed consent to
participate in the study. The study protocol conformed to the
ethical guidelines of the 1975 declaration of Helsinki and had
received an a priori approval by the Ethical committee of
Karolinska Institutet, Stockholm, Sweden and local ethics
approval for gene expression analysis at Heriot-Watt University,
Edinburgh, Scotland.
Study protocol
In order to determine the mitochondrial protein synthesis rates
an intravenous bolus injection of L- [
2H5] phenylalanine was given
to the patients over a period of 10 minutes (45 mg6kg
21 body
weight, 10 atom% excess (APE)) [21]. Blood samples were taken
before (time 0) and at 5, 10, 15, 30, 50,70 and 90 minutes after the
phenylalanine injection for determination of the L- [
2H5]
phenylalanine enrichment in plasma. Muscle biopsies were
obtained from the lateral portion of the vastus lateralis muscle,
10–20 cm above the knee, at 90 and 92 minutes after the bolus
injection on the left and right leg respectively. The biopsies were
obtained using a Bergstro ¨m biopsy needle after local anaesthesia in
the ICU patients and just after sedation in the control patients.
The biopsies were divided into smaller portions, frozen into liquid
nitrogen and stored at 280uC until analysis.
The muscle biopsies were analyzed for in vivo mitochondrial
protein synthesis rate, mitochondrial enzyme activities (citrate
synthase and complex I and IV of the mitochondrial respiratory
chain) and a marker of oxidative stress capacity (Superoxide
dismutase (SOD)). In addition, mRNA levels were measured using
real time qPCR and Affymetrix micro-array analysis. From our
previous study it is clear that the between-patient variation of the
mitochondrial enzyme measurements is high, therefore measure-
ments in the present study were carried out in both legs to further
examine this issue. For the mRNA analyses limited material was
available and therefore only one leg was studied in 24 patients (16
septic and 8 controls) for the qPCR and 21 patients (13 septic and
8 controls) for the micro-array analysis.
Measurements of enzyme activities
Muscle samples were homogenized in a KCL buffer (100 mM
KCl, 50 mM Tris/HCl, 5 mM MgCl2, 1.8 mM ATP and 1 mM
EDTA) to obtain a 5% homogenate [8,22]. Part of the
homogenate was stored frozen at 280uC. The remaining
homogenate was used to isolate mitochondria by subsequent
centrifugations [8,22]. The mitochondrial pellet intended for
enzyme activity measurements was suspended in SET buffer
(0.25 M sucrose, 2 mM EDTA, 10 mM Tris, pH 7.4) and stored
frozen until analysis at 280uC. Activities of citrate synthase,
mitochondrial respiratory chain complexes I and IV and
superoxide dismutase (SOD) were analyzed in both total
homogenate and isolated mitochondria. All assays were spectro-
photometric and performed on a Konelab 20 Analyzer (Thermo
electron corporation, USA) at 37uC as described previously [8,22].
SOD activity was analysed using a Ransod kit (Randox
Laboratories Ltd, UK).
Mitochondrial protein synthesis
Mitochondria were isolated as described above, but the
mitochondrial pellet were dissolved and washed twice with 4%
sulfosalicylic acid (SSA). The pellets were subsequently dissolved in
0.3 M NaOH and the protein concentrations of the samples were
determined using a DC-protein assay kit (Bio-Rad Laboratories,
Hercules, CA, USA). The proteins were then precipitated and
washed twice in 4% (w/v) SSA. The remaining pellets were
hydrolyzed at 110uC for 24 hours in 6 M HCl. After cooling, the
samples were dried by vacuum centrifugation.
The dried samples were prepared for gas chromatography-mass
spectrometry analysis as described previously [23]. The dried
protein hydrolysates were dissolved in 220 ml of 0.5 M sodium
citrate buffer (pH 6.3) and filtered through a 0.22 mm centrifugal
tube. Phenylalanine standards containing 0–0.114 APE (atom
percent excess) were dissolved in the same amount of the sodium
citrate buffer. Samples and standards were decarboxylated in L-
tyrosine decarboxylase to convert phenylalanine into phenyleth-
ylamine at 50uC over night. Subsequently, 100 ml of 6 M NaOH
was added and after centrifugation at 16,0006g, the samples were
extracted in ether and then in 0.1 M HCl and dried. The samples
were derivatized in 25 ml MTBSTFA [N-methyl-N-(t-butyldi-
methylsilyl)trifluoroacetamide]/ethyl acetate(1/1, v/v) at 60uC for
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2H5]-phenylethylamineand phenylethylamine
was determined by GC-MS (Agilent 5973n; Agilent technologies,
Stockholm, Sweden). Ions m/z 180 (m+2) and m/z 183 (m+5) were
analyzed. Plasma free phenylalanine was prepared and analyzed by
GC-MS as described previously [21]. The enrichment of [
2H5]-
phenylalanine in plasma was determined by monitoring the ions m/
z 336 and 341. The enrichment of protein-bound [
2H5]
phenylalanine was calculated from the ratio of m+5/m+2 using
the standard curves. The protein synthesis rate was calculated as:
FSR (% =24 h )~Ep|1440|100=A
Where FSR is the fractional protein synthesis rate, Ep is the protein-
bound enrichment of [
2H5] phenylalanine (APE), A is the area
under the curve for [
2H5] phenylalanine enrichment (APE) in
plasma over time.
Quantitative real-time PCR
The transcript levels of several mitochondrial protein subunits
encoded by either nuclear or mitochondrial DNA were measured
by real-time (RT)-PCR. The nuclear encoded subunits of
mitochondrial enzymes citrate synthase (CS var1 and 2), complex
IV (COXIV) and succinate dehydrogenase (SDHA) were
measured. For the mitochondrial-encoded genes, subunits of
complex I (mtND4, mtND6) and complex IV (mtCO1) and
cytochrome B (mtCYB) were measured. In addition, transcription
factors NRF-1 and NRF-2a/GABP as well as coactivators PGC-
1a and -1b were quantified. These transcriptional regulators
control the expression of nuclear encoded mitochondrial proteins.
To further examine factors which directly regulate mtDNA
encoded genes, we determined TFAM, TFB1M and TFB2M
expression. In addition, given our previous data, we quantified
several mitochondrial protease genes, two that are part of the AAA
proteases family and located in the inner membrane of the
mitochondria (YME1L1 and SPG7/paraplegin) and two located
in the mitochondrial matrix (LON and CLPP).
Total RNA was isolated from muscle samples using TRIzol
(Invitrogen, Stockholm, Sweden) and quantified using a Nano-
drop spectrophotometer. cDNA was prepared from 1 mg of RNA
using random hexamer primers and reverse transcription reagents
(Applied biosystems) in a final volume of 40 ml. Gene expression
was quantified in triplicates as previously described [24].
Oligonucleotide primers were designed using a primer design
centre (http://www.probelibrary.com/) and synthesized by Invi-
trogen (Stockholm, Sweden). To avoid amplification of nuclear
DNA the primers were designed to amplify across exon-exon
boundaries. Mitochondrial DNA contamination can not be
excluded using this procedure and a ‘contamination test’ was
therefore performed. Total RNA was utilized instead of cDNA
using primers towards a mitochondrial-encoded gene (MTCO1)
and the resulting amplification plot was used to indicate the
amount of mtDNA contamination. The mtDNA contamination
was negligible (less than 3%) and thus had no impact on the
analysis. The delta CT (cycle threshold) values, calculated based on
correction to 18sRNA, were calculated for each sample and
statistical analysis was applied to this raw data. The linear value of
each patient was then compared to the mean of all the control
values to get an estimate of the mean increase/decrease and the
variation between the samples.
Affymetrix Microarray
Hybridization, washing, staining and scanning of the arrays
were performed according to manufacturer’s instructions
(Affymetrix, Inc. http://www.affymetrix.com/). The Array design
can be found at https://www.affymetrix.com. We utilized the
Affymetrix U133+2 array platform with RNA preparations. Data
presented in the paper was quality controlled using the Microarray
Suite software (MAS 5.0). All array data were normalized through
implementations of the MAS5 algorithm, to a global scaling
intensity of 100. As a mean to control the quality of the individual
arrays, all arrays were examined using hierarchical clustering to
identify outliers prior to statistical analysis in addition to the
standard quality assessments including scaling factors and
housekeeper 59/39 ratios. No array failed these standard quality
assessment procedures although patient 9 was a clear ‘outlier’.
Nevertheless, patient 9 did not influence the global gene
expression analysis, while for the qPCr analysis (using a separate
RNA/Analysis technology) patient 9 did demonstrate the highest
expression value for NRF2 (See results) indicating that this
patient’s gene expression status was genuinely altered to a much
greater extent.
Array analysis strategies
We have previously demonstrated that it can be difficult to
predict the impact of applying arbitrary filtering criteria prior to
statistical analysis [25]. We therefore relied on several statistical
models to present, analyze and interpret our data with and without
arbitrary pre-filtering of gene lists. The microarray data was
subjected to global normalization using the Robust Multi-Array
Average expression measure (RMA) Bioconductor (www.biocon-
ductor.org) and the output compared with MAS5.0. On this
occasion 90% of RMA identified genes were found in the MAS5
data set while analysis of the smaller RMA data set provided a very
similar result (in terms of Gene ontology analysis of differentially
expressed genes). Thus, we used MAS5.0 for the remaining
analysis as the point of array analysis is to generate a large yet
robust data set. There is some argument that using the MAS5.0
generated present-absent calls can improve the sensitivity of the
differential gene expression analysis [26]. We chose to remove
probe sets where they were declared ‘absent’ across all chips. The
normalized log2-file was analyzed with the Significance Analysis of
Microarray (SAM) in R (http://www-stat.stanford.edu/,tibs/
SAM/). SAM provides a list of ‘‘significant’’ genes and attempts to
estimate of the false discovery rate (FDR), which represents the
percentage of genes that could be identified by chance. SAM
assign a score to each gene/probe set as an index of relative
difference between groups. For the data presented in the
manuscript, genes were considered significantly changed in ICU
patients, when a delta value corresponding to the number of false
significant genes of 5% (q-value), and an average fold change of 2,
was achieved. For the pathway analysis a stricter statistical cut-off
was utilized (1% FDR), while presented pathways were colored by
1.5 FC and 5% FDR so that the robust trends within pathways
could be visualized. Finally, due to lack of sufficient RNA please
note we did not profile the two patients with the very high protein
synthesis rates on Affymetrix arrays and thus these patients did not
drive nor inform the array analysis.
We used the web-based bioinformatics tool, Ingenuity pathway
analysis (IPA, http://www.ingenuity.com), which is based on .1.7
Million published articles, to discover networks regulated in the
skeletal muscle of ICU patients, compared with age matched
controls. IPA is a knowledge database generated from the peer-
reviewed scientific publications that enables discovery of biological
networks in gene expression data, determining the functions most
significant to those networks. Gene name identifiers or Affymetrix
probe set ID’s were uploaded into IPA and queried against all
other genes stored in the IPA knowledge database. Each
Mechanisms of Muscle Wasting
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identifier in the IPA knowledge database. Probe sets representing
genes having direct interactions with genes in the IPA knowledge
database are called ‘‘focus’’ genes, which were then used as a
starting point for generating functional networks. Each generated
network is assigned a score according to the number of
differentially regulated focus genes in our dataset. These scores
are derived from negative logarithm of the P indicative of the
likelihood that focus genes found together in a network due to
random chance. Scores of 14 or higher have 99.9% confidence
level of significance. In reporting our findings we focus on
networks with a substantially higher confidence limit and thus
represent strong evidence for a given biological pathway being
activated in ICU patients. It should be noted however that while
the database extends the interpretation beyond mRNA transcript
levels (as network genes don’t have to be differentially expressed at
the mRNA level) the database is finite and reflects current
knowledge.
Detection of microRNA hsa-mir-21 expression by using
real-time PCR
MicroRNA expression was analysed using the TaqmanH
MicroRNA assays developed by Applied Biosystems that detects
mature miRNA. A microRNA-specific looped primer is used for
the reverse transcription, thus extending the microRNA sequence
enabling detection with TaqmanH real-time PCR. Samples were
analysed for the expression of hsa-mir-21 (4373090, Applied
Biosystems) and the endogenous reference, RNU48 (4373383,
Applied Biosystems), which is a small nuclear RNA (which we
have found to be stable in human muscle through comparison with
18s). Ten ng of total RNA was reverse transcribed using the
TaqManH MicroRNA Reverse Transcription Kit (Applied
Biosystems, PN 4366597) according to instructions. In short, a
mastermix was prepared resulting in a final concentration in a 15-
ml volume of 1 mM dNTP, 50 U MuLV Multiscribe reverse
transcriptase, 16 reverse transcription buffer and 3.8 U RNase
Inhibitor. RNA was added, and aliquots made followed by
addition of the microRNA-specific reverse transcription looped
primer to a final concentration of 16 RT-primer. The reactions
were gently mixed and briefly spun down and run in a PTC-
100
TM(MJ Research Inc.) with conditions at 16uC for 30 min,
42uC for 30 min, and 85uC for 5 min.
For the real-time PCR, the TaqManH 26 Universal PCR
Master Mix, No AmpEraseH UNG was used (Applied Biosystems,
PN 4324020). The samples were run on a 7900HT Fast Real-
Time PCR System (Applied Biosystems) on the 9600 emulation
mode in triplicates of 20 ml per well. Real-time PCR conditions
were; 95uC for 10 minutes followed by 50 cycles of 95uC for
15 sec and 60uC for 1 min. All reactions were run singleplex and
analysed and quantified using the DDCt method. Data are
expressed as fold change from controls.
miRNA target prediction and Gene Ontology Class
The binding of the miRNA to the target mRNA occurs in the
‘‘seed’’ region of the miRNA, representing nt 2–7 of the 59end of
the mature miRNA and the 39 untranslated region (UTR) of the
mRNA. We used Gene Ontology analysis to obtain an overview of
the main classes of biological functions of genes predicted to be
targets for miRNA-21 and thus we are able to apply a degree of
statistical rigor beyond predicted target lists only. For miRNA
target prediction categorized by Gene Ontology, we used EASE
(Version 2 with updated annotation files, 2006) and a miRNA
target gene list (representing target genes conserved across murine
and human genes) developed based on Ensemble and miRNA
sequences obtained from the Sanger Institute (http://microrna.
sanger.ac.uk/sequences/). EASE analysis predicts biological
functions of target genes for the miRNA of interest and enlists a
false discovery rate (FDR) and an EASE score, which we
calculated using 500 permutations/iterations. For prediction of
miRNA-21 target sites we used Targetscan (http://www.targets-
can.org/, release 4.0).
Statistics
Most measurements were normally distributed according to the
Kolmogorov-Smirnov test (Statistica, Softstat, Tulso, OK, USA).
Since not all parameters were normally distributed we analysed all
data (except the micro-array data) both using the Student’s t-test
and Mann-Whitney U-test. Data are presented as means and
standard deviation. Statistical analysis for the micro-array is
described in detail above.
Results
Included patients
ICU patient characteristics are given in Table 1. Despite their
initial diagnosis all included patients were diagnosed with severe
sepsis/septic shock [20] sometime during their disease. At the time
of the biopsy, all patients were circulatory stable and not suffering
from severe sepsis/septic shock. At the time of biopsy all patients
were considered to suffer from multiple organ failure, although
three patients had SOFA score below 4. All but one patient
received intravenous insulin (20–260 IE per day of Actrapid, Novo
Nordisk) to control hyperglycemia. Glucose levels were between 3
and 12 mM on the day of the study. As controls, 1 woman and 9
men were included, the median age was 70 (range 48–76) and
median body mass index (BMI) was 27.4 kg6m
21. The control
subjects underwent elective surgery for either gallbladder disease
or inguinal hernia.
Muscle mitochondrial enzyme activities are decreased
with sepsis
There were no significant differences between left and right legs
in any of the enzyme and in vivo protein synthesis analyses such that
allresultsarepresentedasthemeanvalueobtainedfromtwomuscle
biopsies. The activity of citrate synthase was 25% lower in the septic
patients as compared to the controls (p=0.0003; t-test) (Table 2).
Mitochondrial respiratory chain complexes I and IV were
respectively 49% and 33% lower in the patients when expressed
per muscle weight (complex I p=0.0002, complex IV p=0.0003; t-
test) (Table 2). However, no statistically significant difference was
observed when expressed per citrate synthase activity (p=0.10 and
0.13 respectively; t-test) suggesting that it was the total mitochon-
drial content that had declined. In isolated mitochondria, the
activity of complex I was not statistically significantly different
between controls and patients (p=0.11; t-test), while intriguingly
the activity of complex IV was 60% greater in the patients
(p=0.0003; t-test) (Table 2). Superoxide dismutase activity in
muscle homogenate was not different between the patients and the
controls (p=0.79; t-test), yet the activity in isolated mitochondria
was 100% higher in the patients (p=0.011; t-test) (Table 2). We
carried out protein and gene expression analysis to investigate the
cause of these alterations in enzyme capacity.
The decreased mitochondrial function is not due to a
decreased in vivo protein synthesis rate
The amount of mitochondrial protein and therefore muscle
mitochondrial content is the balance between mitochondrial
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mitochondrial function in muscle of septic patients is due to
a decreased synthesis of mitochondrial proteins, in vivo
protein synthesis rates of mitochondrial protein was deter-
mined. No significant difference in mitochondrial protein
synthesis was obtained between the patients and controls
(p=0.35; t-test) (Figure 1A) albeit the patients did demon-
strate a greater variability in synthesis rates, where some
appeared to have a substantially elevated fractional synthesis
rate.
Table 1. Patient characteristics.
Diagnosis Age/sex ICU days* Survival SOFA
APACHE
II** Glucocorticoid Nutrition*** Sedation
Vassopressor agents
Abdominal aortic
aneurysm, pneumonia
60/F 2 S 7 12 Suplementation EN Propofol yes
Pneumonia 47/M 1 S 9 19 None PN Propofol yes
Stroke, pneumonia, cardiac
arrest
63/M 42 D. day 82 8 19 Suplementation PN+EN None no
Respiratory failure (surg) 72/F 1 S 5 22 Suplementation EN Propofol/midazolam yes
Sepsis 77/M 2 S 1 27 Suplementation EN Propofol yes
Respiratory failure, COPD 57/F 1 S 6 30 Replacement PN+EN Propofol yes
Respiratory failure (surg) 68/M 2 S 2 25 None PN+EN Propofol no
Eosofageal resection, COPD 77/M 7 S 5 21 None PN Propofol/midazolam/ketogan yes
Respiratory failure, COPD 69/F 1 S 6 21 Replacement EN Propofol/midazolam/ketogan yes
Pneumonia, COPD 77/M 3 S 5 39 Replacement PN Propofol yes
Abdominal aortic aneurysm 73/F 35 D. day 95 4 16 Suplementation PN+EN Propofol/ketogan yes
Multiple rib fracture 74/M 6 D. day 16 9 19 None PN+EN Propofol yes
Respiratory failure and AMI 66/F 2 S 4 21 Replacement PN+EN Propofol yes
Pneumonia 69/M 2 S 7 30 None PN Propofol yes
Respiratory failure 48/M 2 S 7 14 None PN Propofol/ketogan no
Abdominal sepsis (surg),
COPD
71/F 1 D. day 13 12 29 Suplementation PN Propofol yes
Abdominal sepsis (surg),
COPD
25/F 6 S 3 13 None PN+EN Propofol yes
Mean6SD 64614 6.8611.8 5.962.8 22.267.1
Mean6SD for control subject 64610
SOFA; Sequential Organ Failure Assessment score, AMI; Acute Myocardial Infarction; COPD; Chronic Obstructive Pulmonary Disorder, PN; parenteral nutrition, EN; Enteral
nutrition, S; Survivor, D, death, d; day, surg; surgery
* Days spent in the ICU at the time of muscle biopsy
** APACHE II score at admission to the ICU
*** Nutrition was given
at 20–25 kcal/kg/day including supplementation of glutamine.
doi:10.1371/journal.pone.0003686.t001
Table 2. Enzyme activities.
ICU (n=17) Controls (n=10)
Citrate synthase muscle (mmol6min
216g
21 ww) 18.764.3* 24.364.6
Complex I muscle (mmol6min
216g
21 ww) 1.960.8 * 2.961.0
Complex I muscle (U6U
21 CS) 0.1060.03 0.1260.04
Complex I isolated mitochondria (U6U
21 CS) 0.4160.12 0.3560.06
Complex IV muscle (mmol6min
216g
21 ww) 8.162.6* 11.562.9
Complex IV muscle (U6U
21 CS) 0.4360.07 0.4660.09
Complex IV isolated mitochondria (U6U
21 CS) 1.4260.27* 0.9460.21
Total SOD (U6g
21 ww) 217630 220617
Mitochondrial SOD (U6U
21 CS) 1.2560.85* 0.5060.15
Mean and standard deviation of mitochondrial enzyme activity measurements in leg muscle from ICU patients with sepsis induced multiple organ failure.
* p,0.05
(both for Student’s t-test and Mann Whitney U-test). ICU intensive care unit patient, ww wet weight, CS citrate synthase, SOD superoxide dismutase
doi:10.1371/journal.pone.0003686.t002
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incomplete mitochondrial biogenesis and increased
expression of mitochondrial protease genes
To specifically address whether transcriptional activation of
mitochondrial related genes was suppressed we utilised real time
qPCR. None of the mitochondrial and nuclear genes, encoding
for mitochondrial related enzymes were significantly different
between patients and controls (Figure 1B). Further, while there
was greater variation for the mtDNA-encoded genes than for the
nuclear encoded oxidative phosphorylation (OXPHOS) genes
the tendency was for up regulation. Assembly of mitochondria
networks involves hundreds of gene products and while
OXPHOS related mRNA expressio nm a yh a v eb e e ns t a b l ei n
patients, disruption of regulators of mitochondrial organelle/
network formation could also result in loss of function.
Surprisingly, the proposed master regulators of mitochondrial
biogenesis; NRF1, PGC1a and PGC1b were unchanged,
however NRF2a/GABP expression was 67% higher in the septic
patients (p=0.0163; t-test) (Figure 1C). Convincingly, the
mtDNA regulating factors TFAM, TFB1M and TFB2M were
all increased significantly (by 109, 108 and 72% respectively) and
these nuclear encoded genes are regulated by NRF2a/GABP
(Figure 1D).
T h u sw h i l ew ec l e a r l yd e m o n s t r a t e dd e c r e a s e dm i t o c h o n d r i a l
enzyme activities, this was not due to lack of mRNA coding for
OXPHOS proteins. Rather, increased expression of several of
the transcriptional regulators of biogenesis suggests that there
was a clear yet partially effective stimulus for mitochondrial
biogenesis. This did not, however, result in an increased synthesis
of mitochondria but rather only selective activation of NRF2a/
GABP and NRF2a/GABP target genes. However, the ICU
patients were treated with insulin therapy to overcome hyper-
glycemia [7] and experimental hyperinsulinaemia has been
shown to increase the expression of some oxidative phosphory-
lation genes [27]. It therefore occurred to us that the insulin
therapy may be responsible for alterations in NRF2a/GABP and
that such changes were not specific to MOF. We analysed the
response of NRF2a/GABP to exogenous insulinin vivo in humans
and using a muscle cell line model. First we examined the
expression of NRF2a/GABP in the C2C12 muscle cell line,
exposed to supra-physiological levels of insulin and we could not
detect any induction of NRF2a/GABP expression or its target
genes TFB1M and TFB2M (Supplemental Figure S1), suggesting
that increased NRF2a/GABP and NRF2a/GABP target gene
expression in the ICU patients was not a consequence of the
insulin therapy but rather some more specific response to altered
mitochondrial function. We also observed a reduction in PGC1a
mRNA in insulin treated C2C12 cells, consistent with the in vivo
study by Southgate et al [28]. In addition, to verify that insulin
would not increase NRF2a/GABP in vivo we utilised RNA
derived from a previously published [29] hyperinsulineamia
clamp study in healthy volunteers (5 hrs, 149.2+/26.9
mIU6l
21) and we found that NRF2a/GABP and PGC1a
mRNA expression was unaltered compared with control (data
not shown). It appears unlikely that the robust activation of
NRF2a/GABP and target genes in ICU patients reflects the
insulin therapy. Connectivity analysis was carried out using
NRF2a (GABPA and GABPB) and Affymetrix data (See below)
further illustrates the response of some NRF2a/GABP related
genes (Supplemental Figure S2). We also evaluated if mitochon-
Figure 1. Protein synthesis and gene expression of mitochondria in muscle of septic and age-matched control subjects. In vivo
fractional synthesis rate (FSR) of mitochondrial protein in skeletal muscle from ICU patients with sepsis induced multiple organ failure and age-
matched control subjects are expressed in %/day (top left panel). Each dot represents one patient and the bar represents the mean value. mRNA level
of subunits of nuclear and mitochondrial encoded enzymes (top right panel), transcription factors controlling expression of nuclear encoded proteins
(lower left panel) and transcription factors regulating the transcription of mitochondrial DNA (lower right panel) in skeletal muscle of septic patients.
The changes in mRNA levels are expressed in percent of controls (n=8) and are presented as mean and standard deviation. The genes marked with
mt are mitochondrial encoded. *p,0.05 (both for Student’s t-test and Mann-Whitney U-test).
doi:10.1371/journal.pone.0003686.g001
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mitochondrial proteases LON and CLPP demonstrated an
increase in the patients compared to controls of 48 and 39%
respectively (P=0.0029 and 0.0166 respectively; t-test) while
the AAA metalloprotease subunits paraplegin (SPG7) and
YME1L1 genes did not differ between the patients and
controls. These results support the idea that in muscle of
patients with sepsis, deregulated mitochondrial biogenesis may
promote mitochondrial proteases expression to cope with failure
in coordinated protein formation. However, the substantial loss
of skeletal muscle mitochondrial content appears dispropor-
tionate compared with the global yet incomplete activation of
biogenesis (See below) and thus it was important to identify the
molecular signals coordinating these gross alterations in muscle
phenotype.
Affymetrix analysis of ICU patient skeletal muscle shows
a large number of genes that are differentially expressed,
with the majority up regulated
To establish a more global analysis of muscle phenotype we
subjected the muscle samples to Affymetrix gene array analysis
f o l l o w e db yo u rc o m p a r a t i v ea r r a ya n a l y s i ss t r a t e g y[ 3 0 , 3 1 ] .T h e
data discussed in this publication have been deposited in NCBI’s
Gene Expression Omnibus and are accessible through GEO
Series accession number GSE13205 (http://www.ncbi.nlm.nih.
gov/geo/query/acc.cgi?acc=GSE13205). The micro-array
analyses were initially used to obtain a more global picture of
the mitochondrial genes in skeletal muscle during sepsis. In
addition, this allowed us to generate a detailed picture of ICU
patient muscle status and also facilitated a direct comparison with
various animal models which have been developed to study
muscle wasting and inflammation [32,33] to aid future drug
discovery efforts. This later analysis allows us to infer associations
between changes in patient muscle with specific programmes
activated by muscle wasting or muscle disuse - data that would
otherwise not be possible to generate, given the critical status of
such individuals. This enormously valuable analysis should also
help further validate these animal models for drug target
validation purposes.
We found that 2080 probe sets (corresponding to 1457 unique
genes/identifiers) were up-regulated in ICU patients, compared
with control subjects (.2 fold change with a 5% FDR
(Supplemental data sheet S1). We found fewer down regulated
genes, with 783 significant probe sets representing 525 unique
genes/identifiers (.2 fold change with a 5% FDR). Examination
of the Affymetrix expression data allowed us to take a more global
view on the regulation of mitochondrial gene expression. From a list
of 342 genes annotated as being ‘mitochondrial’ on the U133+2
micro-array chip, expression of 82 genes were regulated in muscle
of the septic patients (Supplemental data sheet S2). Of these 82
genes, only 8 were down regulated and remarkably 74 were up
regulated. From the down regulated genes only one was a specific
component of the OXPHOS machinery (NADH dehydrogenase 1
subunit C1). Within the up regulated genes, the largest change
observed was for the mitochondrial superoxide dismutase gene,
with a 16-fold increased expression. This result is remarkably
consistent with the increased activity of the mitochondrial
superoxide dismutase protein activity (Table 2). Thus analysis of
the mitochondrial gene responses, as detected using the Affymetrix
platform, strongly supports our conclusion that activation of many
but not all mitochondrial genes occurred; a potentially adaptive,
yet clearly ineffective, reponse at maintaining mitochondrial
capacity.
Gene ontology analysis of Affymetrix analysis identifies
broad molecular programmes activated in ICU patient
skeletal muscle
To capture a broad assessment of the molecular processes
represented by the ,2000 modulated genes, we utilised gene
ontology (GO) analysis [34]. We found that regulation of
apoptosis, proteosome function, ion homeostasis and kinase
signalling were modulated and these appeared to us as rather
predictable findings (Supplemental data sheet S1). Gene ontology
analysis of the down regulated list indicated that there was a
dramatic loss of unique muscle related gene expression demon-
strating that the patient muscle tissue was undergoing a de-
differentiation process. Down regulated genes also indicated a loss
of expression of numerous extracellular matrix gene ontology
groups, which are known to be central to skeletal muscle
remodelling and gain in physiological capacity [30,35]. Thus,
despite the lack of change in global protein synthesis, the types of
protein being synthesised are most probably extremely different in
the skeletal muscle of ICU patients.
As we wish to intervene to prevent the loss of muscle tissue
function, it is important to determine which biological pathways
were regulating this shift in muscle phenotype. To examine this
question, we took a number of approaches. Using a multiple array
analysis strategy [30,31] we utilised the extensive animal models of
muscle wasting, inactivity and inflammation from the Goldberg
laboratory [32,33]. While it is implausible to directly assess muscle
function in the ICU setting, this comparative analysis allows us to
contrast ICU patients with models of muscle atrophy, muscle
inflammatory and muscle inactivity along the lines presented by
Sacheck et al [33]. It also facilitates discussion of the utility of such
models and whether they accurately represent human muscle
wasting disorders. Secondly, we utilised Ingenuity pathway
analysis to establish which signalling processes or unique gene-
networks may be coordinating the altered tissue phenotype
(Ingenuity IPA, http://www.ingenuity.com).
Altered atrogen expression, described in catabolic animal
models, are similar in the septic patients, except for the
energy metabolism genes
In two recent publications, common genes up regulated or
down regulated in animal models with muscle wasting have been
identified [32,33]. In the first study animal models for fasting,
cancer cachexia, uremia and diabetes mellitus identified 120
unique genes involved in catabolism, and the authors named these
‘atrogens’. In a second paper these genes were compared with two
animal models of disuse induced muscle wasting, leading to 53
commonly changed genes. We compared these results to our data
from MOF patients and found good agreement, with the
exception of the genes involved in energy metabolism (Supple-
mental data sheet S3). As described above, the majority of
mitochondrial genes involved in energy production are either
unchanged in muscle of the septic patients or modestly increased,
and this agrees with our previous conclusions that in humans,
mitochondrial related mRNAs are not highly responsive to
alterations in muscle usage in humans [24,30].
When comparing the septic patient responses in gene
expression, with animal models of disuse, in general a much
poorer agreement is observed. This indicates that muscle
inactivity, inevitable in the septic ICU patients, doesn’t dominate
the muscle phenotype seen in these patients, while the in vivo disuse
phenotype observed in the various model systems is highly
reproducible. Pathway analysis revealed that the animal model
atrogens formed several networks, of which estradiol was
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support of this novel re-analysis of the data from the Goldberg
laboratory, it has been demonstrated that estrogen status regulates
muscle recovery from atrophy [36] and in the ICU patients ERS1
(estrogen receptor 1) was 3-fold down regulated. Notably estrogen
receptors are present also in male skeletal muscle [37] and are
proposed to attenuate atrophy [38]. Based on our analysis of the
Goldberg laboratory models, and the fact that our patients present
a similar muscle gene expression profile, interventions which
promote muscle estrogen receptor activation may be worth
investigating in the ICU setting.
Pathway analysis identifies modulation of key canonical
pathways and networks in MOF ICU patients
We found several significantly modulated canonical signalling
pathways which understandably linked with sepsis. Nuclear Factor
Erythroid 2-like-2 is a transcription factor (Nrf2, not to be
confused with mitochondrial related gene NRF2a/GABP), which
responds to a variety of mediators including inflammation. The
Nrf2 mediated oxidative stress response pathway was highly
regulated in ICU patients (Figure 2, p=1.4610-5 and supple-
mental data set S4) and recently it was shown that in Nrf2 -/-
mice, mortality and inflammation is greatly enhanced in response
to sepsis [39]. Nrf2 appears important for the regulation of
glutathione synthesis and cellular detoxification processes. Resto-
ration of glutathione levels in muscle of septic patients seems to be
a prioritised system [40] that could be regulated via Nrf2. Our
data suggests that Nrf2 plays a major role in muscle tissue during
sepsis, perhaps coordinating the oxidative stress response.
We found that insulin receptor signalling pathway was signifi-
cantlymodulatedinthe patients (Figure3andsupplementaldataset
S4). Given the critical role of insulin resistance in these patients [41]
itwasinformative inthat molecules immediately down streamofthe
insulin receptor appeared to be down regulated, such as IRS1,
CD36 and JAK1/2 (a tyrosine kinase associated with cytokine and
metabolic signalling). The exception was suppressor of cytokine
signalling 3 (SOC3) which was 7 fold increased in expression
(Figure 3 and supplemental data set S4) and this would be consistent
with attempts to suppress the deleterious impact of MOF induced
cytokine signalling [42] on insulin action as SOC3 can oppose
inflammatory IL6 signalling. More distal insulin targets, such as
mTOR and hormone sensitive lipase were up-regulated. These
responses would suggest to us that the exogenous insulin interacts
with excessive cytokine signalling to influence skeletal muscle gene
expression. Additional canonical systemsappeared activated such as
JAK/Stat signalling and PPARa/RXRa. With respect to the later,
AMPK and adiponectin expression was both elevated (both also
associated with aspects of mitochondrial biogenesis), while in the
same PPARa/RXRa influenced signalling system, down regulation
of Stat5b indicated a potentially negative interaction between
growth hormone action on muscle and PPARa. Activation of
PPARa by using an agonist has been shown to improve
mitochondrial content and function in skeletal muscle of children
with severe burn injury [43,44] providing a second example of
where our data directs us to a drug target.
Finally, Gene Network analysis (based on gene expression
changes and nearest molecular neighbours) demonstrated a large
number of regulated gene expression networks in skeletal muscle
of septic patients. The nuclear phosphoprotein MYC (V-MYC
avian myelocytomatosis viral oncogene homolog) was 9 fold
induced and was central to the highest scored network that
included induction of 3 subunits of eukaryotic translation initiation
factor 3 (Supplemental figure S4 and supplemental data set S4).
Additional significant networks included ESR1 (down regulated)
and genes associated with the atrogen analysis and TGFb
connected genes known to be important for muscle tissue
remodelling (Supplemental figure S5, supplemental data set S4).
Protein synthesis and altered processing of microRNAs
Interestingly, given that global protein synthesis rates were
unchanged in the patients, 27 translation related genes were up-
regulated (e.g. Supplemental figure S4), while perhaps critically
this up-regulated functional family did not include the rate-limiting
translation initiation 59 cap-binding protein, EIF4E [45]. Un-
changed expression of EIF4E was found in an IL-6 influenced
network demonstrating evidence for vastly up regulated IL-6
receptor and STAT3 (Fig. 4 and supplemental data set S4).
Intriguingly, this network analysis of the Affymetrix array also
included a 5-fold increase of the pri-microRNA transcript of mir-
21 in ICU patients and microRNAs are selective regulators of
protein synthesis [46]. In addition, XPO5, the exportin
responsible for transporting the mature miRNA from the
nucleus, was also increased substantially in the patients. We
therefore went on to analyse the abundance of the mature and
active microRNA, mir-21 in ICU patients and controls using real
time qPCR method. The ICU patients displayed a variable and
non-significant 50% increase in the mature mir-21 expression
levels (p=0.13), see Figure 4 insert, contrasting with the primary
transcript. This suggests to us that suppressed microRNA
processing or export may be occurring, representing a plausible
mechanism explainingg l o b a ll o s so fc o o r d i n a t e dm u s c l eg e n e
expression and thus worthy of further investigation. This is
especially plausible as Gene ontology analysis of the predicted
targets of mir-21 suggest it should inhibit genes involved in
ubiquitin ligase and JAK-STAT activity, both which were
processes shown to be significantly up regulated in the
transcriptomes of the patients. Thus failure to produce sufficient
mir-21 may well have contributed to the activation of these
pathways.
Discussion
In this study we investigated the nature of the mitochondrial
dysfunction found in intensive care using enzymology, protein flux
analysis and transcriptomics. While some mitochondrial enzymes
activities were 25–49% lower in skeletal muscle of patients treated
in the ICU for sepsis induced multiple organ failure in comparison
with a control group of similar age it was abundantly clear that this
was not due to either a global reduction in mitochondrial gene
transcripts or to impaired in vivo total mitochondrial protein
synthesis. Our initial analysis demonstrated a selective activation
of NRF2a/GABP and its target genes suggesting partial activation
of mitochondrial biogenesis, while global analysis of 342
mitochondrial genes supported this interpretation. Comparative
array analysis discovered that while many atrophy and inflamma-
tion responses are conserved across species, the metabolic gene
responses in rodent models do not represent a response seen in
ICU patients. This is particularly important, as gene expression
profiling without consideration of physiological context can
produce misleading conclusions [30]. Finally, network analysis
was able to pin-point oxidative stress related pathway activation,
modulation of the insulin signalling pathway and indicated that
skeletal muscle in ICU patients was undergoing a de-differentia-
tion process regardless of duration in the ICU.
Metabolic homeostasis and mitochondrial dynamics
In our previous study, as well as in the present one, we found
low activities of mitochondrial respiratory chain complexes I and IV,
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the low activities of complexes I and IV were not present when
expressed per citrate synthase activity, indicating a net decrease in
mitochondrial content had occurred. Low activities of mitochondrial
enzymesinskeletalmusclehavebeenshownbeforeinanimalmodels
for sepsis [11,15,16,17,18] and in critically ill patients [12,14,47,48].
Most patient studies included patients in the acute septic or
cardiogenic shock [14,47,48] whereas our patients have been
stabilized in the ICU and have developed multiple organ failure.
During the acute critical phase results indicate a decreased function
of the respiratory chain enzymes whereas the later phase of sepsis is
characterized by a general decrease in mitochondrial content
[49,50]. One might assume that the loss of mitochondrial content
reflects muscle inactivity resulting in decreased gene activation [24]
or sepsis induced atrophy disrupting mitochondrial biogenesis [32].
However,neither appearsto betrue. Firstly, theinvivo mitochondrial
protein synthesis in the septic ICU patients was not different from
thatinthecontrolsubjects,indicatingthatsufficientmRNAtemplate
existed for translation. Secondly, targeted qPCR analysis demon-
strated that the expression of several nuclear encoded oxidative
phosphorylation genes did not differ between the groups, while there
was a trend for up-regulation of mtDNA encoded oxidative
phosphorylation genes and global analysis identified .80 modestly
up regulated nuclear encoded mitochondrial related genes. Critical-
ly, this pattern of gene expression differs markedly from muscle
unloadinginhumans[24]andfromanimalmodelsofatrophy-sepsis,
indicating that our findings are not driven by inactivity nor are they
adequately represented by preclinical models. These results indicate
for the first time, that the observed lower mitochondrial content in
muscle of septic ICU patients with multiple organ failure is not due
Figure 3. Insulin signalling canonical pathway. Ingenuity analyses of micro-array data indicated a canonical pathway involving insulin signalling
as significantly changed in muscle of the septic patients in comparison with age-matched controls. Gene descriptions can be found in supplemental
data sheet S5. Red (and pink) means significantly increased gene expression and blue decreased. The ‘strength’ of the colour is an indication of how
up regulated the gene was (with darker red being more up-regulated). Grey is a highly connected gene (to the transcript network that is altered) but
itself is not altered at the mRNA level. Blue/Red hybrids are genes identified in the data base where the protein is actually at least two different genes
and 1 sub-unit is down, while the other is up.
doi:10.1371/journal.pone.0003686.g003
Figure 2. Nuclear Factor Erythroid 2 canonical pathway. Ingenuity analyses of micro-array data indicated a canonical pathway around nuclear
Factor Erythroid 2 (Nrf2) as one of the most significantly (p=1.4610-5) changed in muscle of the septic patients in comparison with the age-matched
controls. Gene descriptions can be found in supplemental data sheet S5. Red (and pink) means significantly increased gene expression and blue
decreased. The ‘strength’ of the colour is an indication of how up regulated the gene was (with darker red being more up-regulated). Grey is a highly
connected gene (to the transcript network that is altered) but itself is not altered at the mRNA level. Blue/Red hybrids are genes identified in the data
base where the protein is actually at least two different genes and 1 sub-unit is down, while the other is up.
doi:10.1371/journal.pone.0003686.g002
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the protein synthesis process.
The balance between the biogenesis pathways and the rate of
mitochondrial protein degradation regulates tissue mitochondrial
content. The coordinate gene expression for the estimated 1500 or
so mitochondrial proteins, is under tight control by these different
transcriptional regulators [51,52,53,54,55,56,57,58]. The nuclear
encoded mitochondrial proteins are regulated by NRF1, NRF2a/
Figure 4. Interleukin- 6 and micoRNA –mir 21- related network. Ingenuity analysis indicated a network including interleukin-6 and the
microRNA mir21 to have many significantly changed genes in the septic patients compared with the controls. Data in the micro-array is of pre-
microRNA of mir-21 where as the qPCR data (insert) is of the mature and active microRNA. Data in the insert are fold change in mir-21 in septic
patients compared with controls and are presented as means6SEM. Gene descriptions can be found in supplemental data sheet S4. Red (and pink)
means significantly increased gene expression and blue decreased. The ‘strength’ of the colour is an indication of how up regulated the gene was
(with darker red being more up-regulated). Grey is a highly connected gene (to the transcript network that is altered) but itself is not altered at the
mRNA level. Blue/Red hybrids are genes identified in the data base where the protein is actually at least two different genes and 1 sub-unit is down,
while the other is up.
doi:10.1371/journal.pone.0003686.g004
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replication and transcription is greatly influenced by TFAM,
TFB1M and TFB2M [56,58]. In the present study we found high
mRNA levels of all three transcriptional regulators that act on
mitochondrial DNA, and intriguingly selectively high NRF2a/
GABP levels, a transcription factor that regulates the nuclear
encoded TFAM; TFB1M and TFB2M. We also determined that
the selective activation of NRF2a/GABP was unlikely to be
caused by exogenous insulin. The inability of mitochondrial
protein synthesis to sustain mitochondrial capacity may therefore
reflect a lack of coordinated expression of all the transcription
factors needed for an increased mitochondrial biogenesis. The
reason for the lack of coordinated increase in mitochondrial
biogenesis genes in these patients needs to be elucidated and may
ultimately be manipulated to improve patient outcome.
Regulation of protein synthesis and potential alterations
in microRNA processing
It has previously been reported that mitochondrial protein
synthesis and gene expression are decreased in septic rats [11,59].
Like our present comparative analysis, this supports the idea that
rodent models may be inappropriate for studying mitochondrial
dynamics. The unchanged mitochondrial protein synthesis rates
are in line with the synthesis rates of other muscle proteins in the
septic ICU patients. The very characteristic loss of total muscle
protein in these patients is also accompanied by normal synthesis
rates of total muscle protein [19] while our transcriptomics
indicates that the actual proteins being made, will clearly be
substantially different from control skeletal muscle. Future detailed
proteomic analyses combined with ribosomal RNA analysis [60]
will allow us to define which proteins are now being synthesised.
The translational initiation factors (EIFs) are central compo-
nents of the protein translation machinery and EIF4 is the
proposed rate limiting factor for protein translational. While the
partners of EIF4E, EIF4A1 (Helicase), EIF4G1 (scaffold protein)
and EIF3S10 were all up-regulated in the ICU patients, EIF4E is
unchanged at the mRNA level. In combination with the increased
expression of the tRNA synthetases, MARS, LARS and RARS it
would appear that a substantial yet incomplete attempt was made
to promote muscle protein synthesis, similar to that observed for
the mitochondria. This appears to have failed perhaps reflecting a
lack of up-regulation of EIF4E, however, EIF4E is not considered
to be regulated to a great extent, at the mRNA level [61], and thus
further analysis is merited. Overall, it is clear that the lack of gross
changes in in vivo protein dynamics must obscure critical
alterations in specific protein formation, such that combing
protein measurements with global transcriptomics provides a
powerful solution to understanding the nature of tissue remodel-
ling in multiple organ failure patients.
When looking for novel regulators of altered protein production
from mRNA, microRNA’s as global regulators of protein synthesis
are of great interest [62]. In the ICU patients, we found a
compelling 500% increase in the precursor for mir-21 (pri-mir-21).
When we measured the mature form of mir-21, we observed no
significant change in mir-21 levels (50% increase, p=0.13) in
skeletal muscle of ICU patients when compared with controls.
This is important as it has been recently identified that reduction
in PTEN expression could be a compensatory mechanism to
prevent muscle protein degradation [63] and mir-21 is a validated
target of PTEN [64]. Mature mir-21 is processed from a 3,433
long nucleotide pri-mir-21 [65]. Thus, despite the substantial
increase in the mir-21 precursor, only modest changes in mature
miRNA occurred.
Interestingly, IL-6 is activated in ICU patients [42] and has been
reported to increase mir-21 in tumour cell lines mediated via
STAT3 [66]. The IL-6 receptor increases in skeletal muscle in
response to both acute [67] and chronic [68] stimuli, suggesting an
increased responsiveness to IL-6. We detected a 10-fold increase in
the IL-6 receptor in skeletal muscle of ICU patients, when
compared with healthy controls, along with a 1.8-fold increase in
STAT-3, the intracellular mediator of IL-6 signalling. This suggests
an increased sensitivity to IL-6 and an increased IL-6 response in
the ICU patients and this may explain the substantial increase in
transcriptionof the precursor for mir-21. Whether global processing
of microRNA’s has been disrupted in ICU patients merits further
analysis. It would appear, from this initial analysis, that there is
substantial transcriptional drive to promote mir-21 expression,
while some aspect of the miRNA biogenesis pathway limits
substantial production of this translational blocking RNA species.
Clinical impact for the patient
The loss of muscle mass and function has a profound affect on
mortality and morbidity, not only in the septic ICU patients
included in this study but also in other diseases with more chronic
muscle wasting e.g. cancer, kidney failure and COPD. In the
septic patients the loss of muscle mass as well as mitochondrial
content are not due to an overall decrease in their synthesis rates.
A obvious conclusion from this is that the losses are driven by
increased degradation and that therapeutic aims should be
focussed on modulating inappropriate degradation. However the
present data suggest that a different spectrum of protein will be
synthesised in these patients, and this implies that the precise
profile of proteins being synthesised is altered and thus targeting
protein degradation is not necessarily a logical strategy.
Limitations of the study
A potential limitation of the present study is the heterogeneity of
the included patients. Patients were included at different days of
ICU treatment (range from 1–42 days). It is possible that the
mitochondrial derangements are different at different phases of
disease. However, it is not certain that the duration of ICU stay
represents different phases of the disease. Often patients treated in
the ICU have been ill for a while before, whereas others arrive to
the ICU early after the initial insult. It is therefore difficult to see
length of ICU stay as a measure of time of disease. However when
the patient with a shorter ICU stay (,6 days) were compared with
those with a longer stay ($6 days) no significant difference were
observed (Table 3 and 4). Also post-hoc analyses not including the
2 patients with extreme long ICU treatment (35 and 42 days)
showed exactly the same changes in comparison with the controls
as when including all patients (Table 3 and 4). Most importantly,
global transcript profiling and clustering indicates that all patients
are remarkably similar and develop a specific and clear muscle
phenotype.
However the groups in these post-hoc analyses are rather small
and studies designed to study the temporal changes are needed.
We tried to include a patient population with severe sepsis/septic
shock induced multiple organ failure. Patients not recovering from
an initial sepsis develop multiple organ failure requiring ICU
treatment. The patients we included were not in their septic shock
anymore and had developed multiple organ failure making them
rather comparable. However a few patients with SOFA scores
below 3 were included not fulfilling the criteria for multiple organ
failure. Again post-hoc analyses comparing the ICU patients with
SOFA score over 3 with the controls gave exactly the same
changes and conclusions as before (Table 3 and 4). These post-hoc
analyses show that this apparently heterogeneous group of ICU
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changes and gene expression in skeletal muscle. Another possible
confounding factor is the different treatments that the patients
receive. When performing studies in actual ICU patients we are
dealing with reality and this can not be changed for clinical
reasons. Treatment with corticosteroids is the one most discussed
in relation to muscle dysfunction. However when we compared
the micro-array changes in our patients with the changes induced
with methylprednisole treatment in rats only a 1–2% of the ICU
regulated genes were affected in both the patients and the rat
model [69], indicating that corticosteroid treatment in the ICU
patients contributes little to the observed changes. However affects
of other treatments can not be excluded.
Another limitation of the study is the isolation of mitochondria
done for measuring the enzyme activities and the synthesis rates of
mitochondrial protein. The sequential centrifugations used to
isolate the mitochondria mainly isolate intact mitochondria and
not the damaged mitochondria. Also this procedure isolated
mainly the subsarcolemmal mitochondria from skeletal muscle and
not the intramyofibrillar mitochondria. So when measuring the
enzyme activities in the isolated mitochondria this represents
mainly intact subsarcolemmal mitochondria. This selection of one
subpopulation of the mitochondria is most likely also the
explanation for the different values obtained for complex I and
IV activities expressed per citrate synthase activity in the whole
muscle and the isolated mitochondria. Also the increased complex
IV activity in the isolated mitochondria and not in the whole
muscle could be explained by this. Both the fractional synthesis
rates of the mitochondria and the mitochondrial SOD activity can
not be measured differently than in the isolated mitochondria. It is
possible that the synthesis rates in the non-isolated mitochondria
are decreased in the patients. However the gene expression data
Table 4. Post hoc analyses on mRNA levels measured with
qPCR expressed as percentage of control.
,7 days ICU
(n=14) P=
ICU SOFA.3
(n=14) p=
CS 122640 0.40 124636 0.14
SDHA 93632 0.49 100627 0.98
COXIV 103631 0.93 108627 0.53
mtND4 2186176 0.06 2116177 0.06
mtND6 2786268 0.05 2506272 0.18
mtCYB 2206176 0.36 2096180 0.46
Mt CO1 1716123 0.51 1656124 0.55
NRF1 104637 0.84 107635 0.67
NRF2/GABP 169668 0.02 175663 0.005
PGC1A 121685 0.95 136680 0.23
PGC1B 107653 0.91 109652 0.79
TFAM 174694 0.02 192691 0.003
TFB1M 193663 0.0005 121658 ,0.0005
TFB2M 167661 0.004 182664 0.0008
LON 149643 0.005 162638 ,0.0005
CLPP 150652 0.01 153649 0.004
SPG7 107626 0.68 112619 0.18
YME1L1 186694 0.02 185697 0.004
Data is given as mean and standard deviation. p for Student’s t-test. ICU
intensive care unit patient, ww wet weight, CS citrate synthase, SOD superoxide
dismutase
doi:10.1371/journal.pone.0003686.t004
Table 3. Post hoc analyses on enzyme activities and mitochondrial synthesis rates.
,6 days ICU (n=12) .6 days ICU (n=5) p=
Citrate synthase muscle (mmol6min
216g
21 ww) 19.563.2 17.166.1 0.31
Complex I muscle (mmol6min
216g
21 ww) 1.961.6 1.661.1 0.57
Complex IV muscle (mmol6min
216g
21 ww) 8.562.0 7.264.0 0.35
Total SOD (U6g
21 ww) 212620 224642 0.43
Mitochondrial SOD (U6U
21 CS) 0.960.4 1.661.3 0.15
Synthesis rates (%/day) 2.360.6 4.663.9 0.05
,7 days ICU (n=15) Controls (n=10) p=
Citrate synthase muscle (mmol6min
216g
21 ww) 19.464.1 24.364.6 0.01
Complex I muscle (mmol6min
216g
21 ww) 1.960.8 2.961.0 0.01
Complex IV muscle (mmol6min
216g
21 ww) 8.662.5 11.562.9 0.01
Total SOD (U6g
21 ww) 217627 220617 0.71
Mitochondrial SOD (U6U
21 CS) 1.160.8 0.560.1 0.03
Synthesis rates (%/day) 2.460.6 2.560.4 0.91
ICU SOFA.3 (n=14) Controls (n=10) p=
Citrate synthase muscle (mmol6min
216g
21 ww) 18.864.1 24.364.6 0.006
Complex I muscle (mmol6min
216g
21 ww) 1.860.7 2.961.0 0.007
Complex IV muscle (mmol6min
216g
21 ww) 8.162.4 11.562.9 0.005
Total SOD (U6g
21 ww) 212627 220617 0.39
Mitochondrial SOD (U6U
21 CS) 1.160.6 0.560.1 0.007
Synthesis rates (%/day) 3.462.7 2.560.4 0.30
Data is given as mean and standard deviation. p for Student’s t-test. ICU intensive care unit patient, ww wet weight, CS citrate synthase, SOD superoxide dismutase
doi:10.1371/journal.pone.0003686.t003
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normal synthesis as measured in the isolated mitochondria.
In summary, we demonstrated that while the skeletal muscle of
septic ICU patients with multiple organ failure have reduced
mitochondrial content, this is not associated with a gross failure in
biogenesis of mitochondria since both in vivo protein synthesis and
mitochondrial related mRNA abundance were sustained. How-
ever, loss of coordination of key elements of mitochondrial
biogenesis was apparent, such that maturation of mitochondrial
and mitochondrial networks may have still been compromised,
resulting in activation of some specific mitochondrial matrix
proteases. Further, in this first ever analysis of the global
transcriptional responses in ICU patients, we find a substantial
loss of muscle specific genes, a global oxidative stress response
related to most probably cytokine signalling, altered insulin related
signalling and a substantial overlap between patients and muscle
wasting/inflammatory animal models. Failure to process mir-21
may have contributed to the activation of these signalling
pathways, while such impairment hints at a wider problem with
miRNA formation and hence control of tissue phenotype. Finally,
we were able to demonstrate that the phenotype of skeletal muscle
in ICU patients is not merely one of inactivity, it appears to be an
actively remodelling tissue, influenced by several mediators, all of
which may be open to manipulation with the aim to improve
clinical outcome
Supporting Information
Figure S1 Expression of mitochondrial transcription factors in
C2C12 cells with and without insulin. Differentiated C2C12 cells
were incubated with insulin from day 5 to day 6 (24 h) and
expression of NRF2a, TFB1m and TFB2m were all measured by
qPCR (white bars, water; grey bars, 0.6 mM insulin; black bars,
6 mM insulin). None of the mRNA levels were changed by insulin
in relation to the controls. Values are given as mean6SEM.
Found at: doi:10.1371/journal.pone.0003686.s001 (0.28 MB TIF)
Figure S2 NRF2a/GABP network. Ingenuity analyses of micro-
array data indicated a network around NRF2a/GABP as
significantly changed in muscle of the septic patients in comparison
with age-matched controls. Gene descriptions can be found in
supplemental data sheet S4. Red (and pink) means significantly
increased gene expression and blue decreased. The ‘strength’ of the
colour is an indication of how up regulated the gene was (with
darker red being more up-regulated). Grey is a highly connected
gene (to the transcript network that is altered) but itself is not altered
at the mRNA level. Blue/Red hybrids are genes identified in the
data base where the protein is actually at least two different genes
and 1 sub-unit is down, while the other is up.
Found at: doi:10.1371/journal.pone.0003686.s002 (0.72 MB TIF)
Figure S3 Comparisons of network analyses of atrogens in
animal models and septic patients. Ingenuity network analyses
including the atrogens defined by Golberg et al [32,22] from
catabolic and disuse animal models. The network build around
these genes and related genes are shown. The changes in gene
expression for the animal models are shown on the left and for the
human data from the septic patients on the right. In large changes
are similar except for the energy metabolism related genes which
are downregulated in the animal models and not changed in the
septic patients. An interesting observation is that this network is
closely regulated by estradiol. Gene descriptions can be found in
supplemental data sheet S3. Red (and pink) means significantly
increased gene expression and blue decreased. The ‘strength’ of
the colour is an indication of how up regulated the gene was (with
darker red being more up-regulated). Grey is a highly connected
gene (to the transcript network that is altered) but itself is not
altered at the mRNA level. Blue/Red hybrids are genes identified
in the data base where the protein is actually at least two different
genes and 1 sub-unit is down, while the other is up.
Found at: doi:10.1371/journal.pone.0003686.s003 (0.87 MB TIF)
Figure S4 Myc network. Ingenuity analyses of micro-array data
indicated a network around MYC as most significantly changed in
muscle of the septic patients in comparison with age-matched
controls. Gene descriptions can be found in supplemental data
sheet S4. Red (and pink) means significantly increased gene
expression and blue decreased. The ‘strength’ of the colour is an
indication of how up regulated the gene was (with darker red being
more up-regulated). Grey is a highly connected gene (to the
transcript network that is altered) but itself is not altered at the
mRNA level. Blue/Red hybrids are genes identified in the data
base where the protein is actually at least two different genes and 1
sub-unit is down, while the other is up.
Found at: doi:10.1371/journal.pone.0003686.s004 (0.56 MB TIF)
Figure S5 Tissue remodelling networks. Ingenuity analyses of
micro-array data indicated two network involved in tissue
remodelling as highly significantly changed in muscle of the septic
patients in comparison with age-matched controls. One network is
build around TGFb (a) and the other one around ESR1 (b). Gene
descriptions can be found in supplemental data sheet S4. Red (and
pink) means significantly increased gene expression and blue
decreased. The ‘strength’ of the colour is an indication of how up
regulated the gene was (with darker red being more up-regulated).
Grey is a highly connected gene (to the transcript network that is
altered) but itself is not altered at the mRNA level. Blue/Red
hybrids are genes identified in the data base where the protein is
actually at least two different genes and 1 sub-unit is down, while
the other is up.
Found at: doi:10.1371/journal.pone.0003686.s005 (0.83 MB TIF)
Supplemental data sheet S1 SAM results
Found at: doi:10.1371/journal.pone.0003686.s006 (3.61 MB
XLS)
Supplemental data sheet S2 Expression of mitochondrial
genes from the micro-aray analysis.
Found at: doi:10.1371/journal.pone.0003686.s007 (0.09 MB
XLS)
Supplemental data sheet S3 Comparison of expression of
atrogens identified in muscle of catabolic and disuse animal
models (common to all models) and septic patients.
Found at: doi:10.1371/journal.pone.0003686.s008 (0.05 MB
XLS)
Supplemental data sheet S4 Gene network lists.
Found at: doi:10.1371/journal.pone.0003686.s009 (0.10 MB
XLS)
Supplemental data sheet S5 Canonical Network lists.
Found at: doi:10.1371/journal.pone.0003686.s010 (0.06 MB
XLS)
Acknowledgments
The authors would like to thank the excellent nursing skills of Viveka
Gustavsson at Karolinska University Hospital Huddinge, Nina Johansson,
Ann-Sofie Andersson and Ami Bylund at Ersta Hospital. We also would
like to thank Paul Greenhalf for the kind gift of RNA from his insulin
clamp studies.
Mechanisms of Muscle Wasting
PLoS ONE | www.plosone.org 14 November 2008 | Volume 3 | Issue 11 | e3686Author Contributions
Conceived and designed the experiments: KF IT JW OR. Performed the
experiments: KF IT PK NP BA CS JW JAT. Analyzed the data: KF IT PK
NP CS JW JAT OR. Contributed reagents/materials/analysis tools: NP
BA JW JAT OR. Wrote the paper: KF IT PK NP BA CS JW JAT OR.
References
1. Banwell BL, Mildner RJ, Hassall AC, Becker LE, Vajsar J, et al. (2003) Muscle
weakness in critically ill children. Neurology 61: 1779–1782.
2. Bolton CF (1996) Sepsis and the systemic inflammatory response syndrome:
neuromuscular manifestations. Crit Care Med 24: 1408–1416.
3. De Jonghe B, Cook D, Sharshar T, Lefaucheur JP, Carlet J, et al. (1998)
Acquired neuromuscular disorders in critically ill patients: a systematic review.
Groupe de Reflexion et d’Etude sur les Neuromyopathies En Reanimation.
Intensive Care Med 24: 1242–1250.
4. Larsson L, Li X, Edstrom L, Eriksson LI, Zackrisson H, et al. (2000) Acute
quadriplegia and loss of muscle myosin in patients treated with nondepolarizing
neuromuscular blocking agents and corticosteroids: mechanisms at the cellular
and molecular levels. Crit Care Med 28: 34–45.
5. Care A, Catalucci D, Felicetti F, Bonci D, Addario A, et al. (2007) MicroRNA-
133 controls cardiac hypertrophy. Nat Med 13: 613–618.
6. Herridge MS, Cheung AM, Tansey CM, Matte-Martyn A, Diaz-Granados N, et
al. (2003) One-year outcomes in survivors of the acute respiratory distress
syndrome. N Engl J Med 348: 683–693.
7. Van den Berghe G (2004) How does blood glucose control with insulin save lives
in intensive care? J Clin Invest 114: 1187–1195.
8. Fredriksson K, Hammarqvist F, Strigard K, Hultenby K, Ljungqvist O, et al.
(2006) Derangements in mitochondrial metabolism in intercostal and leg muscle
of critically ill patients with sepsis induced multiple organ failure. Am J Physiol
Endocrinol Metab 291: 1044–1050.
9. Dudley GA, Tullson PC, Terjung RL (1987) Influence of mitochondrial content
on the sensitivity of respiratory control. J Biol Chem 262: 9109–9114.
10. Rooyackers OE, Hesselink MK, Wagenmakers AJ (1997) Contraction failure of
skeletal muscle of rats recovering from critical illness. Clin Sci (Lond) 92:
189–195.
11. Rooyackers OE, Adey DB, Ades PA, Nair KS (1996) Effect of age on in vivo rates
of mitochondrial protein synthesis in human skeletal muscle. Proc Natl Acad
Sci U S A 93: 15364–15369.
12. Vanhorebeek I, De Vos R, Mesotten D, Wouters PJ, De Wolf-Peeters C, et al.
(2005) Protection of hepatocyte mitochondrial ultrastructure and function by strict
blood glucose control with insulin in critically ill patients. Lancet 365: 53–59.
13. Fink MP (2004) Research: advances in cell biology relevant to critical illness.
Curr Opin Crit Care 10: 279–291.
14. Brealey D, Brand M, Hargreaves I, Heales S, Land J, et al. (2002) Association
between mitochondrial dysfunction and severity and outcome of septic shock.
Lancet 360: 219–223.
15. Boczkowski J, Lisdero CL, Lanone S, Samb A, Carreras MC, et al. (1999)
Endogenous peroxynitrite mediates mitochondrial dysfunction in rat diaphragm
during endotoxemia. Faseb J 13: 1637–1646.
16. Brealey D, Karyampudi S, Jacques TS, Novelli M, Stidwill R, et al. (2004)
Mitochondrial dysfunction in a long-term rodent model of sepsis and organ
failure. Am J Physiol Regul Integr Comp Physiol 286: R491–497.
17. Crouser ED, Julian MW, Blaho DV, Pfeiffer DR (2002) Endotoxin-induced
mitochondrial damage correlates with impaired respiratory activity. Crit Care
Med 30: 276–284.
18. Schumer W, Erve PR, Obernolte RP (1971) Endotoxemic effect on cardiac and
skeletal muscle mitochondria. Surg Gynecol and Obstetrics 133: 433–436.
19. Tjader I, Rooyackers O, Forsberg AM, Vesali RF, Garlick PJ, et al. (2004)
Effects on skeletal muscle of intravenous glutamine supplementation to ICU
patients. Intensive Care Med 30: 266–275.
20. Bone RC (1992) Editorial. Abnormal cellular metabolism in sepsis. A new
interpretation. JAMA 267: 1518–1519.
21. McNurlan MA, Essen P, Thorell A, Calder AG, Anderson SE, et al. (1994)
Response of protein synthesis in human skeletal muscle to insulin: an
investigation with L-[2H5]phenylalanine. Am J Physiol 267: E102–108.
22. Fredriksson K, Radell P, Eriksson LI, Hultenby K, Rooyackers O (2005) Effect
of prolonged mechanical ventilation on diaphragm muscle mitochondria in
piglets. Acta Anaesthesiol Scand 49: 1101–1107.
23. Januszkiewicz A, Klaude M, Lore K, Andersson J, Ringden O, et al. (2005)
Determination of in vivo protein synthesis in human palatine tonsil. Clin Sci
(Lond) 108: 179–184.
24. Timmons JA, Norrbom J, Scheele C, Thonberg H, Wahlestedt C, et al. (2006)
Expression profiling following local muscle inactivity in humans provides new
perspective on diabetes-related genes. Genomics 87: 165–172.
25. Larsson O, Wahlestedt C, Timmons JA (2005) Considerations when using the
significance analysis of microarrays (SAM) algorithm. BMC Bioinformatics 6:
129.
26. Choe SE, Boutros M, Michelson AM, Church GM, Halfon MS (2005) Preferred
analysis methods for Affymetrix GeneChips revealed by a wholly defined control
dataset. Genome Biol 6: R16.
27. Stump CS, Short KR, Bigelow ML, Schimke JM, Nair KS (2003) Effect of
insulin on human skeletal muscle mitochondrial ATP production, protein
synthesis, and mRNA transcripts. Proc Natl Acad Sci U S A 100: 7996–8001.
28. Southgate RJ, Bruce CR, Carey AL, Steinberg GR, Walder K, et al. (2005)
PGC-1alpha gene expression is down-regulated by Akt- mediated phosphory-
lation and nuclear exclusion of FoxO1 in insulin-stimulated skeletal muscle.
Faseb J 19: 2072–2074.
29. Stephens FB, Constantin-Teodosiu D, Laithwaite D, Simpson EJ, Greenhaff PL
(2005) Insulin stimulates L-carnitine accumulation in human skeletal muscle.
Faseb J.
30. Timmons JA, Larsson O, Jansson E, Fischer H, Gustafsson T, et al. (2005)
Human muscle gene expression responses to endurance training provide a novel
perspective on Duchenne muscular dystrophy. Faseb J 19: 750–760.
31. Timmons JA, Wennmalm K, Larsson O, Walden TB, Lassmann T, et al. (2007)
Myogenic gene expression signature establishes that brown and white adipocytes
originate from distinct cell lineages. Proc Natl Acad Sci U S A 104: 4401–4406.
32. Lecker SH, Jagoe RT, Gilbert A, Gomes M, Baracos V, et al. (2004) Multiple
types of skeletal muscle atrophy involve a common program of changes in gene
expression. Faseb J 18: 39–51.
33. Sacheck JM, Hyatt JP, Raffaello A, Jagoe RT, Roy RR, et al. (2007) Rapid
disuse and denervation atrophy involve transcriptional changes similar to those
of muscle wasting during systemic diseases. Faseb J 21: 140–155.
34. Hosack DA, Dennis G Jr., Sherman BT, Lane HC, Lempicki RA (2003)
Identifying biological themes within lists of genes with EASE. Genome Biol 4:
R70.
35. Timmons JA, Jansson E, Fischer H, Gustafsson T, Greenhaff PL, et al. (2005)
Modulation of extracellular matrix genes reflects the magnitude of physiological
adaptation to aerobic exercise training in humans. BMC Biol 3: 19.
36. McClung JM, Davis JM, Wilson MA, Goldsmith EC, Carson JA (2006) Estrogen
status and skeletal muscle recovery from disuse atrophy. J Appl Physiol 100:
2012–2023.
37. Wiik A, Gustafsson T, Esbjornsson M, Johansson O, Ekman M, et al. (2005)
Expression of oestrogen receptor alpha and beta is higher in skeletal muscle of
highly endurance-trained than of moderately active men. Acta Physiol Scand
184: 105–112.
38. Sugiura T, Ito N, Goto K, Naito H, Yoshioka T, et al. (2006) Estrogen
administration attenuates immobilization-induced skeletal muscle atrophy in
male rats. J Physiol Sci 56: 393–399.
39. Thimmulappa RK, Lee H, Rangasamy T, Reddy SP, Yamamoto M, et al.
(2006) Nrf2 is a critical regulator of the innate immune response and survival
during experimental sepsis. J Clin Invest 116: 984–995.
40. Flaring UB, Rooyackers OE, Wernerman J, Hammarqvist F (2003) Temporal
changes in muscle glutathione in ICU patients. Intensive Care Med 29:
2193–2198.
41. Thorell A, Rooyackers O, Myrenfors P, Soop M, Nygren J, et al. (2004)
Intensive insulin treatment in critically ill trauma patients normalizes glucose by
reducing endogenous glucose production. J Clin Endocrinol Metab 89:
5382–5386.
42. Leonidou L, Mouzaki A, Michalaki M, DeLastic AL, Kyriazopoulou V, et al.
(2007) Cytokine production and hospital mortality in patients with sepsis-
induced stress hyperglycemia. J Infect 55: 340–346.
43. Cree MG, Newcomer BR, Herndon DN, Qian T, Sun D, et al. (2007) PPAR-
alpha agonism improves whole body and muscle mitochondrial fat oxidation,
but does not alter intracellular fat concentrations in burn trauma children in a
randomized controlled trial. Nutr Metab (Lond) 4: 9.
44. Cree MG, Zwetsloot JJ, Herndon DN, Qian T, Morio B, et al. (2007) Insulin
sensitivity and mitochondrial function are improved in children with burn injury
during a randomized controlled trial of fenofibrate. Ann Surg 245: 214–221.
45. Mamane Y, Petroulakis E, Martineau Y, Sato TA, Larsson O, et al. (2007)
Epigenetic activation of a subset of mRNAs by eIF4E explains its effects on cell
proliferation. PLoS ONE 2: e242.
46. Valencia-Sanchez MA, Liu J, Hannon GJ, Parker R (2006) Control of
translation and mRNA degradation by miRNAs and siRNAs. Genes Dev 20:
515–524.
47. Corbucci GG, Gasparetto A, Candiani A, Crimi G, Antonelli M, et al. (1985)
Shock-induced damage to mitochondrial function and some cellular antioxidant
mechanisms in humans. Circ Shock 15: 15–26.
48. Gasparetto A, Corbucci GG, Candiani A, Gohil K, Edwards RH (1983) Effect
of tissue hypoxia and septic shock on human skeletal muscle mitochondria.
Lancet 2: 1486.
49. Helliwell TR, Coakley JH, Wagenmakers AJM, Griffiths RD, Campbell IT, et
al. (1991) Necrotizing myopathy in critically-ill patients. Journal of Pathology
164: 307–314.
50. Helliwell TR, Griffith RD, Coakley JH, Wagenmakers AJM, McClelland P, et
al. (1990) Muscle morphology and biochemistry in critically-ill patients. J Neurol
Sci 98 (suppl): 329.
51. Robinson CE, Wu X, Nawaz Z, Onate SA, Gimble JM (1999) A corepressor and
chicken ovalbumin upstream promoter transcriptional factor proteins modulate
peroxisome proliferator-activated receptor-gamma2/retinoid X receptor alpha-
Mechanisms of Muscle Wasting
PLoS ONE | www.plosone.org 15 November 2008 | Volume 3 | Issue 11 | e3686activated transcription from the murine lipoprotein lipase promoter. Endocri-
nology 140: 1586–1593.
52. Scarpulla RC (2002) Transcriptional activators and coactivators in the nuclear
control of mitochondrial function in mammalian cells. Gene 286: 81–89.
53. Taivassalo T, Fu K, Johns T, Arnold D, Karpati G, et al. (1999) Gene shifting: a
novel therapy for mitochondrial myopathy. Hum Mol Genet 8: 1047–1052.
54. Kelly M, Keller C, Avilucea PR, Keller P, Luo Z, et al. (2004) AMPK activity is
diminished in tissues of IL-6 knockout mice: the effect of exercise. Biochem
Biophys Res Commun 320: 449–454.
55. Goffart S, Wiesner RJ (2003) Regulation and co-ordination of nuclear gene
expression during mitochondrial biogenesis. Exp Physiol 88: 33–40.
56. Gleyzer N, Vercauteren K, Scarpulla RC (2005) Control of mitochondrial
transcription specificity factors (TFB1M and TFB2M) by nuclear respiratory
factors (NRF-1 and NRF-2) and PGC-1 family coactivators. Mol Cell Biol 25:
1354–1366.
57. Fernandez-Silva P, Enriquez JA, Montoya J (2003) Replication and transcription
of mammalian mitochondrial DNA. Exp Physiol 88: 41–56.
58. Falkenberg M, Gaspari M, Rantanen A, Trifunovic A, Larsson NG, et al. (2002)
Mitochondrial transcription factors B1 and B2 activate transcription of human
mtDNA. Nat Genet 31: 289–294.
59. Callahan LA, Supinski GS (2005) Downregulation of diaphragm electron
transport chain and glycolytic enzyme gene expression in sepsis. J Appl Physiol
99: 1120–1126.
60. Larsson O, Li S, Issaenko OA, Avdulov S, Peterson M, et al. (2007) Eukaryotic
translation initiation factor 4E induced progression of primary human mammary
epithelial cells along the cancer pathway is associated with targeted translational
deregulation of oncogenic drivers and inhibitors. Cancer Res 67: 6814–6824.
61. Richter JD, Sonenberg N (2005) Regulation of cap-dependent translation by
eIF4E inhibitory proteins. Nature 433: 477–480.
62. Filipowicz W, Bhattacharyya SN, Sonenberg N (2008) Mechanisms of post-
transcriptional regulation by microRNAs: are the answers in sight? Nat Rev
Genet 9: 102–114.
63. Hu Z, Lee IH, Wang X, Sheng H, Zhang L, et al. (2007) PTEN expression
contributes to the regulation of muscle protein degradation in diabetes. Diabetes
56: 2449–2456.
64. Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, et al. (2007)
MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in
human hepatocellular cancer. Gastroenterology 133: 647–658.
65. Lu C, He JC, Cai W, Liu H, Zhu L, et al. (2004) Advanced glycation endproduct
(AGE) receptor 1 is a negative regulator of the inflammatory response to AGE in
mesangial cells. Proc Natl Acad Sci U S A 101: 11767–11772.
66. Hennig G, Loffler G, Wieland OH (1975) Active and inactive forms of
pyruvatedehydrogenase in skeletal muscle as related to the metabolic and
functional state of the muscle cell. FEBS Lett 59: 142–145.
67. Keller P, Penkowa M, Keller C, Steensberg A, Fischer CP, et al. (2005)
Interleukin-6 receptor expression in contracting human skeletal muscle:
regulating role of IL-6. Faseb J 19: 1181–1183.
68. Keller C, Steensberg A, Hansen AK, Fischer CP, Plomgaard P, et al. (2005)
Effect of exercise, training, and glycogen availability on IL-6 receptor expression
in human skeletal muscle. J Appl Physiol 99: 2075–2079.
69. Almon RR, DuBois DC, Yao Z, Hoffman EP, Ghimbovschi S, et al. (2007)
Microarray analysis of the temporal response of skeletal muscle to methylpred-
nisolone: comparative analysis of two dosing regimens. Physiol Genomics 30:
282–299.
Mechanisms of Muscle Wasting
PLoS ONE | www.plosone.org 16 November 2008 | Volume 3 | Issue 11 | e3686